A September stock screen is drawing attention to three low-priced, U.S.-listed companies with very different business models: electric-vehicle maker NIO Inc., Southeast Asian technology platform Grab Holdings Ltd. and Medicare Advantage insurer Clover Health Investments Corp. The Simply Wall St screen grouped the three under its “financially fit penny stocks” theme, emphasizing operating quality and financial resilience rather than share price alone.

The timing matters. The Federal Reserve on September 16 raised the federal funds target range by 25 basis points to 3.75% to 4%, saying inflation remained elevated even as economic activity continued to expand at a solid pace. Higher rates can increase the cost of capital and make investors less tolerant of businesses that require repeated external financing, putting greater emphasis on revenue growth, margins, cash generation and balance-sheet durability.

NIO is the largest operating story among the three in terms of manufacturing intensity. The Shanghai-based electric-vehicle company reported 107,658 vehicle deliveries during the second quarter of 2026, up 49.4% from the same period a year earlier. Total second-quarter revenue reached RMB32.14 billion, or about $4.74 billion, representing a 69.1% year-over-year increase. Vehicle sales rose 80.1%, while gross margin improved to 18.4% from 10% in the year-earlier quarter.

Those figures give investors a measurable operating thesis rather than a purely speculative one: whether NIO can convert rising deliveries and improving unit economics into sustainable profitability. Its expanding portfolio includes the core NIO brand as well as ONVO and FIREFLY, allowing the company to address more price segments. NIO also continues to differentiate itself through its charging and battery-swap infrastructure, an ecosystem designed to strengthen customer retention and create service revenue beyond the initial vehicle purchase.

The risks remain substantial. Electric vehicles require heavy spending on product development, factories, sales networks and infrastructure, and China’s EV market remains intensely competitive. Faster revenue growth does not automatically translate into positive free cash flow. For U.S. shareholders, NIO also carries the additional considerations associated with owning American depositary shares of a China-based company, including currency, regulatory and geopolitical exposure.

Grab presents a different model. The Nasdaq-listed company operates a Southeast Asian “superapp” spanning ride-hailing, food and parcel delivery, payments and other financial services. Its investor-relations materials show that the company reported record second-quarter 2026 results in August, raised full-year guidance and announced a $750 million share-repurchase program. That combination makes Grab’s inclusion on a low-priced-stock screen notable because its investment case increasingly depends on whether scale can translate into durable profitability rather than simply user growth.

Grab’s financial-services operations are particularly important to that transition. The company has spent years building payments, lending and other financial products alongside its mobility and delivery businesses. That strategy creates cross-selling opportunities because drivers, merchants and consumers already interact with the platform frequently. If financial services expand without a disproportionate rise in credit losses, they could add a higher-value layer to the broader ecosystem.

But that same expansion introduces risks distinct from Grab’s transportation business. Lending requires disciplined underwriting, credit-loss management and regulatory compliance across multiple countries. Investors also have to assess whether stronger earnings can persist as the company continues investing in growth initiatives, including technology and autonomous-mobility partnerships. Grab’s relatively large market capitalization also demonstrates why the “penny stock” label can be misleading when applied solely because a stock trades at a low nominal price.

Clover Health is the most directly U.S.-focused company on the list. The Nashville-area healthcare company operates Medicare Advantage plans and uses its Clover Assistant technology platform to provide physicians with clinical information and decision-support tools. In its second-quarter release, Clover said it delivered positive GAAP net income, continued Medicare Advantage membership growth and improved its full-year 2026 guidance across key metrics.

For Clover, the central issue is medical-cost discipline. Health insurers collect premiums but must accurately price the expected cost of member care. Even strong membership growth can damage earnings if claims rise faster than anticipated. Clover’s strategy is built partly around using technology to improve care management and physician decision-making, with the goal of producing better health outcomes while controlling medical expenses.

The company’s recent profitability and upgraded outlook give investors more concrete metrics to track than were available during the earlier stages of Clover’s life as a public company. Still, Medicare Advantage remains exposed to reimbursement changes, risk-adjustment rules, utilization trends and competitive pricing. Those variables can move margins sharply from year to year, making execution more important than the stock’s nominal share price.

The broader lesson from the three-company screen is that low share prices do not create a common investment profile. NIO depends on vehicle volumes, manufacturing economics and EV competition. Grab depends on platform monetization, financial-services execution and regional consumer demand. Clover depends on insurance pricing, medical costs and Medicare policy. Treating all three simply as “penny stocks” can obscure those underlying business differences.

It is also important to separate exchange-listed companies with substantial revenue from the smallest microcap securities. FINRA says penny stocks are typically associated with very small companies trading below $5, while noting that low-priced stocks can trade either over the counter or on national exchanges. The regulator warns that low-priced securities can be highly volatile and, particularly when liquidity and public information are limited, vulnerable to manipulation.

NIO, Grab and Clover Health are not obscure OTC issuers: all three trade on major U.S. exchanges and provide regular financial disclosures. That does not eliminate risk. Instead, it shifts the analysis toward whether their operating trends justify current valuations and whether they can finance growth without materially weakening shareholder returns.

For investors watching September’s low-priced-stock market, the next signals are likely to come from company execution rather than the “penny stock” label itself. NIO’s delivery momentum and margins, Grab’s path to sustained profitability and Clover Health’s medical-cost performance provide three distinct benchmarks. In a higher-rate environment, the market may reward companies that demonstrate improving fundamentals—but low share prices alone remain a poor substitute for balance-sheet analysis, cash-flow scrutiny and an assessment of business-specific risks.